Key facts
- SpliceBio’s last known valuation is $84.5M (Feb 2022).
- It has raised $198.0M; the latest was Later Stage VC ($134.7M) in Jun 2025.
- Notable investors include New Enterprise Associates, EQT Life Sciences, Gilde Healthcare, Novartis Venture Fund, Caixa Capital Risc — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for SpliceBio
- ·The full record, as it builds
Funding rounds
No funding rounds for SpliceBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SpliceBio
Operator of a biotechnology company intended to develop genetic medicines through protein-splicing gene therapy. The company's platform allows addressing of adeno-associated viruses, both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted and further used to treat patients that suffer from incurable genetic diseases, enabling clients to develop and produce biotherapeutics that overcome the limitations of natural inteins.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2012
- Employees
- 45
- Website
- splice.bio/
- Ownership
- Privately Held (backing)
SpliceBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SpliceBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SpliceBio in its N-PORT filings yet. We sweep new filings monthly.